A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

NCT02127710 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillary Renal Cell Cancer

Interventions

DRUG: AZD6094

Sponsor

AstraZeneca

Collaborators

[object Object]